Effect of Atorvastatin on the Disease Activity and Severity of Rheumatoid Arthritis: Double-Blind Randomized Controlled TrialCorrespondence Address :
Dr. Mehrdad Dargahi-Malamir,
Department of Internal Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Introduction: HMG-CoA (3-hydroxy-3- methylglutary lcoenzyme A) reductase inhibitors (statins) have anti-inflammatory properties which may be particularly useful in rheumatoid arthritis to suppress disease activity and inflammatory factors.
Aim: The purpose of this clinical trial was to determine anti-inflammatory properties of statins in rheumatoid arthritis.
Materials and Methods: Eighty Iranian patients with rheumatoid arthritis, aged between 19 to 75 years were recruited to take part in this randomized, double-blind placebo-controlled trial. Subjects were randomly allocated to two groups to take atorvastatin or placebo 40 mg daily as an adjunct to current disease-modifying anti-rheumatic drugs (DMARDs) treatment. Disease Activity Score-28 (DAS28), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), swollen joint count (SJC) & tender joint count (TJC) were assessed before and after three months intervention.
Results: Analysis was based on intention to treat. DAS28 significantly declined in the atorvastatin group in comparison with placebo (p< 0.001). SJC, TJC, CRP and ESR also were significantly dropped in the atorvastatin group in comparison with placebo.
Conclusion: It can be concluded that atorvastatin can suppress RA activity and inflmmatory factors in RA patients for high to moderate grade of inflmmation.
HMG-CoA, Anti-inflammatory agents, Erythrocyte sedimentation rate, Swollen joint count, Tender joint count
Karim Mowla, Elham Rajai, Ali Ghorbani, Mehrdad Dargahi-MalAmir, Mohammad Bahadoram, Shooka Mohammadi. EFFECT OF ATORVASTATIN ON THE
DISEASE ACTIVITY AND SEVERITY OF
RHEUMATOID ARTHRITIS: DOUBLE-BLIND
RANDOMIZED CONTROLLED TRIAL. Journal of Clinical and Diagnostic Research [serial online] 2016 May [cited: 2018 Oct 20 ]; 10:OC32-OC36. Available from
Date of Submission: Aug 29, 2015
Date of Peer Review: Oct 20, 2015
Date of Acceptance: Dec 30, 2015
Date of Publishing: May 01, 2016
Financial OR OTHER COMPETING INTERESTS: As Declared above.
- Emerging Sources Citation Index (Web of Science, thomsonreuters)
- Index Copernicus ICV 2016: 132.37
- Academic Search Complete Database
- Directory of Open Access Journals (DOAJ)
- Embase & EMbiology
- Google Scholar
- HINARI Access to Research in Health Programme
- Indian Science Abstracts (ISA)
- Journal seek Database
- Popline (reproductive health literature)